Big Pharma talks up Trans Pacific Partnership but profits trump patients:The Age

The Age 17 April 2015

Deborah Gleeson and Pat Neuwelt write that recent pharmaceutical company lobbying repeats many of the same flawed arguments: that increasing intellectual property protection through the TPP will support innovation, investment in research and development, and access to medicines. If this rhetoric is swallowed by our politicians, the rights of transnational drug companies could end up trumping the rights of the public to affordable medicines.